{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:15:01Z","timestamp":1787775301834,"version":"build-2784847793"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea","award":["HI14C3418"],"award-info":[{"award-number":["HI14C3418"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-6030-5","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T13:02:49Z","timestamp":1565787769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody"],"prefix":"10.1186","volume":"19","author":[{"given":"Jiyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee-Taek","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"6030_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","volume":"36","author":"J Larkin","year":"2018","unstructured":"Larkin J, Minor D, D\u2019Angelo S, Neyns B, Smylie M, Miller WH Jr, et al. Overall survival in patients with advanced melanoma who received Nivolumab versus Investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36:383\u201390.","journal-title":"J Clin Oncol"},{"key":"6030_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","volume":"86","author":"O Hamid","year":"2017","unstructured":"Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017;86:37\u201345.","journal-title":"Eur J Cancer"},{"key":"6030_CR3","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","volume":"24","author":"JA Curtin","year":"2006","unstructured":"Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340\u20136.","journal-title":"J Clin Oncol"},{"key":"6030_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175\u201380.","journal-title":"Nature."},{"key":"6030_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.5021\/ad.2014.26.4.485","volume":"26","author":"HS Jang","year":"2014","unstructured":"Jang HS, Kim JH, Park KH, Lee JS, Bae JM, Oh BH, et al. Comparison of melanoma subtypes among Korean patients by morphologic features and ultraviolet exposure. Ann Dermatol. 2014;26:485\u201390.","journal-title":"Ann Dermatol"},{"key":"6030_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10147-007-0751-1","volume":"13","author":"K Ishihara","year":"2008","unstructured":"Ishihara K, Saida T, Otsuka F, Yamazaki N. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol. 2008;13:33\u201341.","journal-title":"Int J Clin Oncol"},{"key":"6030_CR7","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135\u201347.","journal-title":"N Engl J Med"},{"key":"6030_CR8","doi-asserted-by":"crossref","unstructured":"Oh CM, Cho H, Won YJ, Kong HJ, Roh YH, Jeong KH, et al. Nationwide trends in the incidence of melanoma and non-melanoma skin cancers from 1999 to 2014 in South Korea. Cancer Res Treat. 2017.","DOI":"10.4143\/crt.2017.166"},{"key":"6030_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jaad.2009.03.031","volume":"61","author":"J Sng","year":"2009","unstructured":"Sng J, Koh D, Siong WC, Choo TB. Skin cancer trends among Asians living in Singapore from 1968 to 2006. J Am Acad Dermatol. 2009;61:426\u201332.","journal-title":"J Am Acad Dermatol"},{"key":"6030_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","volume":"111","author":"S Diem","year":"2017","unstructured":"Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176\u201381.","journal-title":"Lung Cancer"},{"key":"6030_CR11","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/bjc.2011.100","volume":"104","author":"W Chua","year":"2011","unstructured":"Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil\/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104:1288\u201395.","journal-title":"Br J Cancer"},{"key":"6030_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ebiom.2017.03.029","volume":"18","author":"MR Cassidy","year":"2017","unstructured":"Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, et al. Neutrophil to lymphocyte ratio is associated with outcome during Ipilimumab treatment. EBioMedicine. 2017;18:56\u201361.","journal-title":"EBioMedicine."},{"key":"6030_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"6030_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023\u201331.","journal-title":"Nat Biotechnol"},{"key":"6030_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"6030_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853\u201362.","journal-title":"Lancet."},{"key":"6030_CR17","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-10-2346","volume":"17","author":"Y Kong","year":"2011","unstructured":"Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res. 2011;17:1684\u201391.","journal-title":"Clin Cancer Res"},{"key":"6030_CR18","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.2147\/OTT.S117121","volume":"10","author":"E Munoz-Couselo","year":"2017","unstructured":"Munoz-Couselo E, Adelantado EZ, Ortiz C, Garcia JS, Perez-Garcia J. NRAS-mutant melanoma: current challenges and future prospect. Onco Targets Ther. 2017;10:3941\u20137.","journal-title":"Onco Targets Ther"},{"key":"6030_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","volume":"3","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res. 2015;3:288\u201395.","journal-title":"Cancer Immunol Res"},{"key":"6030_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12943-017-0707-7","volume":"16","author":"A Ocana","year":"2017","unstructured":"Ocana A, Nieto-Jimenez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017;16:137.","journal-title":"Mol Cancer"},{"key":"6030_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.it.2015.11.008","volume":"37","author":"DR Powell","year":"2016","unstructured":"Powell DR, Huttenlocher A. Neutrophils in the tumor microenvironment. Trends Immunol. 2016;37:41\u201352.","journal-title":"Trends Immunol"},{"key":"6030_CR22","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/ijc.30215","volume":"139","author":"S Gandini","year":"2016","unstructured":"Gandini S, Ferrucci PF, Botteri E, Tosti G, Barberis M, Pala L, et al. Prognostic significance of hematological profiles in melanoma patients. Int J Cancer. 2016;139:1618\u201325.","journal-title":"Int J Cancer"},{"key":"6030_CR23","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.","journal-title":"J Natl Cancer Inst"},{"key":"6030_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jaad.2018.03.006","volume":"79","author":"M Garnier","year":"2018","unstructured":"Garnier M, Zaragoza J, Beneton N, Bens G, Meurisse V, Samimi M, et al. High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma. J Am Acad Dermatol. 2018;79:165\u20137.e2.","journal-title":"J Am Acad Dermatol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6030-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T23:07:19Z","timestamp":1597273639000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6030-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6030"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6030-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"assertion":[{"value":"29 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Samsung Medical Center (IRB No. 2018\u201307-080), and informed consent was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"805"}}